NATICK, Mass., June 15 LAWFUEL – Press Release Service — Boston Scientific
Corporation (NYSE: BSX) announced that the U.S. District Court in Delaware
issued a ruling upholding a July 2005 jury verdict in a patent case against
Johnson & Johnson (J&J) (NYSE: JNJ). The ruling denies J&J’s motion to
overturn the verdict, in which the jury had found that J&J’s Cypher(R)
stent product infringed a Boston Scientific drug coating patent. The jury
had also found the patent to be valid.
“We are very pleased that the Court has upheld the jury’s verdict in
favor of Boston Scientific,” said Paul LaViolette, Boston Scientific Chief
Operating Officer. “This ruling reaffirms the strength and innovation of
our drug-eluting stent technologies.”
Boston Scientific is a worldwide developer, manufacturer and marketer
of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
http://www.bostonscientific.com.
This press release contains forward-looking statements. The Company
wishes to caution the reader of this press release that actual results may
differ from those discussed in the forward-looking statements and may be
adversely affected by, among other things, risks associated with clinical
trials, the regulatory approval process, reimbursement policies,
commercialization of new technologies, litigation, the Company’s overall
business strategy and other factors described in the Company’s filings with
the Securities and Exchange Commission.
CONTACT:
Milan Kofol
508-650-8569
Investor Relations
Boston Scientific Corporation
Charles Rudnick
508-650-8660
Media Relations
Boston Scientific Corporation
